Abstract: The invention discloses novel intermediates in the synthesis of Calebin A represented by formula 3. The invention also covers processes for the synthesis of Calebin-A and its analogs using compounds of formula 3.

Abstract: An industrial oil composition contains a mineral or a synthetic oil as a base oil, and a neutral phosphite ester derivative represented by the following formula (B) and a 2,6-di-t-butylphenol derivative represented by the following formula (C) as antioxidants. In the formula (B), Rb21 to Rb24 each independently represent an aliphatic hydrocarbon group of 10 to 16 carbon atoms. In the formula (C), Rc1 represents a straight-chain or a branched alkyl group of 1 to 12 carbon atoms.

Abstract: The present invention discloses a novel endophytic fungi, Ovatospora brasiliensis MTCC 25236 for the bioconversion of curcuminoids to Calebin-A and a method for its isolation from the rhizomes of Curcuma sp. The invention also discloses a method for the bioconversion of curcuminoids to Calebin-A using an endophytic fungi Ovatospora brasiliensis MTCC 25236 and bacterial species, Acinetobacter johnsonii and Pseudomonas putida.

Abstract: A composition comprising caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, caffeoylshikimic acids and their derivatives extracted from any part of oil palm including but not confined to the vegetation liquor of palm oil milling and palm oil mill effluent, and a method for use in the preparation of a composition containing caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, caffeoylshikimic acids and their derivatives.

Abstract: To provide hexaester of bispentaerythritol monoformal, which is a mixed ester of bispentaerythritol monoformal represented by the following formula (I), and carboxylic acids: wherein the carboxylic acids comprise C9 branched aliphatic monocarboxylic acid, and any one of carboxylic acids selected from C4 to C8 aliphatic monocarboxylic acids. The hexaester is used as one component of a refrigerant oil composition, and gives excellent characteristics, such as oxidation stability, lubricity, and low temperature properties, to a refrigerant oil composition.

Abstract: Provided is hexaester of bispentaerythritol monoformal, which comprises the bispentaerythritol monoformal represented by the following formula (I), and any one of carboxylic acids selected from C8 and C9 branched aliphatic monocarboxylic acids: The hexaester has well-balanced excellent characteristics, such as low temperature properties and oxidation stability, and is used for industrial lubricating oil, such as a refrigerant oil composition.

Abstract: A method for inhibiting the crystal growth rate of an amide compound present in a molten polyolefin-based resin and a method for producing a polyolefin-based resin molded article are provided. A phenol compound is incorporated into an amide compound-containing polyolefin-based resin such that a weight ratio, amide compound:phenol compound, is 60:40 to 10:90.

Abstract: The present disclosure relates to a sulfonated benzene compound emitting fluorescence by reaction with hydrogen peroxide, aqueous-dispersed fluorescent nanoprobes applicable for real-time detection of hydrogen peroxide, and a fluorescent nanoprobe fabrication method. The fluorescent nanoprobe contains the following sulfonated benzene compound and water.

Abstract: The present invention, which enables to align a liquid crystal molecule, when no voltage is applied thereto, and also to control pretilt angle of the liquid crystal molecule, relates to a composition for a liquid crystal alignment film comprising components represented by the following (A) to (D): (A) a meta-phenylene diamine derivative represented by the general formula [1]; (B) a meta-phenylene diamine derivative represented by the general formula [2]; (C) a para-arylene diamine represented by the general formula [3]; (D) a tetracarboxylic acid represented by the general formula [4] or a tetracarboxylic acid anhydride represented by the general formula [4?]; (wherein R1 represents an alkyl group having 1 to 6 carbon atoms or the like, R2 represents an alkyl group having 8 to 20 carbon atoms or the like, t moieties of Ra represent an alkyl group having 1 to 3 carbon atoms or the like, n represents an integer of 1 to 3, t represents an integer of 0 to 4, T represents an oxygen atom or the like, Y repre

Abstract: Esters of O-substituted hydroxy carboxylic acids are provided having Formula 1, or 2, or both Formulas 1 and 2: wherein R and R1 are independently selected from the group consisting of substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated C1-C22 alkyl, substituted and unsubstituted C3-C8 cycloalkyl, substituted and unsubstituted C6-C20 carbocyclic aryl, and substituted and unsubstituted C4-C20 heterocyclic; wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen; and wherein n is 1-6. Process of producing esters of O-substituted hydroxy carboxylic acids are also provided.

Abstract: The present application relates to amine salts of prostaglandin analogs and their uses for the preparation of substantially pure prostaglandin analogs. Specific embodiments relate to amine salts of tafluprost and their uses for the preparation of substantially pure tafluprost.

Abstract: Synthetic dicinnamate compounds and their analogs are disclosed that exhibit anti-tumor activity and/or an anti-inflammatory activity, and have beneficial activity principally in destroying cancer cells. Furthermore, methods for the extraction of the extracts are disclosed.

Abstract: The invention relates to a process for the preparation of travoprost of formula (I), comprising that, the compound of formula (II), is stereo selectively reduced, the resulting compound of formula (III), is if desired crystallized, the lactone group of the compound of formula (III) is reduced, the p-phenyl-benzoyl protecting group of the thus obtained compound of formula (IV), is removed, the resulting triol of formula (V), is, if desired after crystallization, transformed by Wittig reaction into the acid of formula (VI), which is then esterified.

Abstract: The invention discloses a novel intermediate for preparing tapentadol and analogues thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogues thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production.

Abstract: The present invention provides a method for converting an aromatic hydrocarbon to a phenol by providing an aromatic hydrocarbon comprising one or more aromatic C—H bonds and one or more activated C—H bonds in a solvent; adding a phthaloyl peroxide to the solvent; converting the phthaloyl peroxide to a di-radical; contacting the di-radical with the one or more aromatic C—H bonds; oxidizing selectively one of the one or more aromatic C—H bonds in preference to the one or more activated C—H bonds; adding a hydroxyl group to the one of the one or more aromatic C—H bonds to form one or more phenols; and purifying the one or more phenols.

Abstract: A radiation-sensitive composition containing a resist compound having a high sensitivity, a high resolution, a high etching resistance, and a low outgas which forms a resist pattern with good shape and a method of forming a resist pattern and novel compositions for forming a photoresist under coat film which is excellent in optical properties and etching resistance and contains substantially no sublimable substance and an under coat film formed by the composition. Radiation-sensitive composition containing a solvent and a cyclic compound having, e.g., a cyclic compound (A) having a molecular weight of 700 to 5000 which is synthesized by the condensation reaction of a compound having 2 to 59 carbon atoms and 1 to 4 formyl groups with a compound having 6 to 15 carbon atoms and 1 to 3 phenolic hydroxyl groups, and a cyclic compound for use in the radiation-sensitive composition.

Abstract: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.

Abstract: Described is the use of specific merocyanine derivatives for protecting body-care and household products from photolytic and oxidative degradation. These compounds perform outstanding UV absorber properties.

Abstract: The disclosure relates to TAK1 inhibitors, compositions, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula (I), pharmaceutical compositions having a compound of formula (I), and methods of treating or preventing cancer by administering an effective amount of a pharmaceutical composition having a compound of formula (I) to a subject in need thereof.

Abstract: The present invention relates to compounds of formula I, which are functionalized phenolic compounds, and polymers formed from the same. Ar—[O—(X)p—R?]q??I Polymers formed from the functionalized phenolics are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.

Abstract: A new and distinct cultivar of Mentha spicata L. named KI-MsEM0042 and characterized by elevated levels of rosmarinic acid and vigorous growth.

Abstract: A new and distinct cultivar of Mentha spicata L. named KI-MsEM0110 and characterized by elevated levels of rosmarinic acid and vigorous growth.

Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

Abstract: The dehydrated alkali metal salts of carboxylic acid are dissolved in the alcohol such as methanol or ethanol or butanol to make their solution in corresponding alcohol. The solution alcohol is further treated with carbon dioxide under pressure or at atmospheric pressure at elevated temperature such as 150 to 200° C. The carboxylic acid gets converted into corresponding alkyl ester and calcium carbonate or sodium carbonate or potassium carbonate as the byproduct. Calcium lactate or sodium lactate or sodium acetate or sodium benzoate or sodium salicylate as alkali metal salt solution prepared in methanol or ethanol or butanol when treated with carbon dioxide under pressure or at atmospheric pressure at elevated temperature gets converted to methyl lactate or ethyl lactate or methyl acetate or methyl benzoate or methyl salicylate as product.

Abstract: The present invention relates to a method of reducing a C—O bond to the corresponding C—H bond in a substrate which could be a benzylic alcohol, allylic alcohol, ester, or ether or an ether bond beta to a hydroxyl group or alpha to a carbonyl group.

Abstract: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, a wound (the compounds assist with wound healing), acne, rheumatoid arthritis, psoriasis, rosacea, and alopecia; Kennedy's disease (spinal and bulbar muscular atrophy, or SBMA), polyglutamine-mediated motor neuron degeneration; cancers such as prostate cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular (liver) cancer, and pancreatic cancer; and other medical conditions described herein. Treatment of such medical conditions includes administering to an individual suffering from a medical condition describe herein, a therapeutically effective amount of any of the disclosed compounds, their derivatives, or pharmaceutical compositions thereof.

Abstract: Disclosed is the use of the compounds represented by formula (I) in the preparation of a medicament against tumor angiogenesis, wherein R1 and R2 are each independently C1-C8 alkylidene group or C2-C8 alkenylidene group; A1 and A2 are each independently aryl, isoaryl, or aryl or isoaryl optionally substituted by halogen, —CN, —NO2, —OH, —SH, —OR3, —SR3, —R3, —R3—OR4, —C(O)R3, —S(O)R3, —S(O)2R3, —NR4R5, —C(O)OR3, —C(O)NR4R5, —O(O)CR4, —S(O)CR4 or —NR4(O)CR5, wherein R3 is C1-C4 alkyl, R4 and R5 are each independently hydrogen, C1-C4 alkyl, aryl or substituted aryl; and X and Y are each independently oxygen; and the compound of formula (I) does not include phenethyl caffeate.

Abstract: The present invention relates to a process for preparing a prostaglandin derivative and an intermediate therefor. In accordance with the present invention, the prostaglandin F (PGF) derivative can be efficiently prepared with high purity by removing the protecting group of a protected prostaglandin E (PGE) derivative obtained from conjugate addition and then stereoselectively reducing the ketone group on the cyclopentanone ring of the PGE derivative.

Abstract: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.

Abstract: The invention discloses a novel intermediate for preparing tapentadol and analogues thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogues thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production.

Abstract: Synthetic dicinnamate compounds and their analogues are disclosed that exhibit anti-tumor activity and/or an anti-inflammatory activity, and have beneficial activity principally in destroying cancer cells. Furthermore, methods for the extraction of the extracts are disclosed.

Abstract: In one aspect, the invention relates methods for inhibiting or preventing muscle atrophy or increasing muscle mass by providing to a subject in need thereof an effective amount of ursolic acid, a derivative thereof, or an analog of the ursane scaffold. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

Abstract: A chewing gum, creamer, powdered supplement or other confection, as a food supplement formulated to combine natural or artificial sweeteners and flavorings with CGA, packaged for retail sale to consumers, for providing an ideal bio-available delivery mode for CGA, a recognized antioxidant and natural metabolic stimulant, as a ready supplement for bioactive immune support and to aid users in management of weight loss, obesity and/or glucose management, or for general health and well-being of users.

Abstract: This invention demonstrates the therapeutic efficacy of Yang-Gan-Wan (YGW) and its active components, especially in the formulation provided by Sheng-Pu Pharmaceutials, Inc., for treating and preventing liver fibrosis. This invention further demonstrates MeCP2 is an important therapeutic target for YGW and its active ingredients' action against liver fibrosis and cirrhosis.

Abstract: A medical product containing either an active ingredient of propolis which is a natural antibiotic or a grapefruit seed extract, and a manufacturing method thereof are provided. The medical product is impregnated with a solution of CAPE (caffeic acid phenethyl ester) or pinocembrin, which is an active ingredient of propolis having antibacterial effects, to increase the antibacterial activity of the medical product due to antibacterial compounds contained in the active component, or the medical product is impregnated with a solution of a grapefruit seed extract such that the extract can exhibit antibacterial activity in the medical product.

Abstract: Process for fractioning and refining natural products obtainable from waste vegetal material and particularly from artichoke (Cynara scolymus) production or from other plants of the Cynara genus such as the cultivated or wild cardoon. The process is based on the use of membrane separation technologies envisaging a tangential microfiltration (MF) phase on the raw decoction, followed by tangential ultrafiltration (UF) on the previous MF permeate and reverse osmosis (RO) on the UF permeate, in order to obtain a retentate rich in concentrated active ingredients and a permeate consisting of ultrapure water that is recycled for the preparation of the decoction. The process enables obtaining purified extracts of high biological valence to be used in the pharmaceutical industry, in the nutraceutic sector, in the cosmetics industry and for innovative products in the food industry.

Abstract: Provided is a process for producing a purified chlorogenic acid-containing preparation, which is useful for the production of a chlorogenic acid-containing beverage with reduced developability of turbidity even in an acidic range. The process for producing a purified chlorogenic acid-containing preparation according to the present invention includes a first step of dispersing or dissolving a chlorogenic acid-containing composition as a starting material in the presence of acid clay or activated clay in a mixed solvent of an organic solvent and water, a second step of removing a deposit from a dispersion or solution obtained by the first step, a third step of adjusting a concentration of chlorogenic acids and pH in a solution, which has been obtained by the second step, to from 1.5 to 10 mass % and from 2 to 4, respectively, and a fourth step of separating the deposit formed in a concentration-adjusted solution obtained by the third step.

Abstract: The invention relates to a method for producing a cross-coupling product of a benzenoid dizonium salt according to the general formula (I), wherein the groups R1, R2, R3, R4, and R5 represent hydrogen, halogen, an alkyl, alkenyl, aryl, alkoxy, aryloxy, nitro, cyano, hydroxy, acetyl, and/or diazo groups independently of each, and X represents BF4, Cl, F, SO3CH3, CO2CH3, PF6, ClO2CH3, or CIO4, comprising the following steps: (a) providing a benzenoid amide, which with the exception of the diazo function has the same substituents R1, R2, R3, R4, and R5 as the benzenoid diazonium salt of the general formula (I), and hydrolytically cleaving the amide to form an amine or providing a corresponding amine, (b) diazotizing the amine thus obtained or provided with a nitrite, and (c) subsequently reacting the benzenoid diazonium salt with a coupling partner in the presence of a catalyst to form a cross-coupling product, wherein the coupling parter is represented by the general formula (II), R6, R7, and R8 are the same or

Abstract: The present disclosure relates to a process for pre-treating raw propolis comprising at least one allergenic activity substance, which comprises reacting propolis with a probiotic microorganism containing one or more cinnamoyl-esterase activity enzymes to obtain a semisolid propolis derivative substantially without or impoverished of allergenic substances. The present invention also relates to a method of purifying semisolid propolis derivative to obtain a hydroalcoholic hydrodispersible propolis derivative.

Abstract: This invention relates to novel coumarin derivative, formulations comprising same, and to methods of making and using these compounds and formulations, which are useful as repellents against insects and/or pests. The compounds also prevent illness and disease caused by insect/pest-borne vectors, and provide safer, more effective alternatives to existing repellents.

Abstract: The present invention provides paraben compositions and associated methods and reagents, particularly useful for the treatment of dermatologic conditions. In some embodiments, provided compositions are formulated for and achieve transdermal delivery, for example by topical administration.

Abstract: The present disclosure relates to a sulfonated benzene compound emitting fluorescence by reaction with hydrogen peroxide, aqueous-dispersed fluorescent nanoprobes applicable for real-time detection of hydrogen peroxide, and a fluorescent nanoprobe fabrication method. The fluorescent nanoprobe contains the following sulfonated benzene compound and water.

Abstract: A composition comprising caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, said caffeoylshikimic acids and their derivatives extracted from any part of oil palm including but not confined to the vegetation liquor of palm oil milling and palm oil mill effluent, and a method for use in the preparation of a composition containing caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, said caffeoylshikimic acids and their derivatives.

Abstract: The present invention provides a compound that can be used within a resist composition, an intermediate compound for the compound, a positive resist composition, and a method for forming a resist pattern.

Abstract: A new and distinct cultivar of Mentha spicata L. named KI-MsEM0042 and characterized by elevated levels of rosmarinic acid and vigorous growth.

Abstract: A method of producing a compound represented by the following general formula (3): [wherein R is a bivalent aliphatic group having a carbon number of 1-16 or a bivalent aromatic group], which comprises a step (i) of reacting a compound represented by the following general formula (1): with a carboxylic acid halide represented by the following general formula (2): [wherein R is a bivalent aliphatic group having a carbon number of 1-16 or a bivalent aromatic group and X is a halogen atom] in the presence of a basic compound to form an ester, and a step (ii) of conducting a heat treatment after the step (i) to decompose an oligomer in the ester.

Abstract: The presently disclosed subject matter provides a method of synthesizing prostaglandins and prostaglandin analogs comprising the ring closing metathesis of compounds of Formula (I). Also provided are novel compounds of Formula (I) and Formula (II). In addition to their use as synthetic intermediates in the presently disclosed methods, compounds of Formula (II) can be used as prostaglandin and/or prostaglandin analog prodrugs.

Abstract: The present invention relates to an alpha-arylmethoxyacrylate derivative, a preparation method thereof and a pharmaceutical composition comprising the same, and the alpha-arylmethoxyacrylate derivative is inhibitory of HIF, which plays an important role in the regulation of genes associated with energy metabolism, vasomotion, angiogenesis and apoptosis and in the response of cells under hypoxic conditions, so that it can be used for preventing or treating of diseases such as cancer, arthritis, psoriasis, diabetic retinopathy and macular degeneration.

Abstract: Disclosed are: labeled NSAIDs compounds which can be produced within a short time, can be used suitably for a PET method, and enable the imaging of cyclooxygenase-2; and a process for producing the labeled NSAIDs compounds. Specifically disclosed are isotope-labeled 2-arylpropionic acid compounds, each of which is a compound represented by general formula (1) (wherein Ar represents an aryl group which may have a substituent; R1 represents anyone selected from 11CH3, CH218F and CF218F; and R2 represents a hydrogen atom, or an alkyl group which may have a branch, wherein a compound wherein Ar is a benzene ring, R1 is 11CH3, and R2 is a hydrogen atom is excluded), or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.